ADVERTISEMENT
LIVE DESK·Global markets desk·Last updated 14s ago
ADVERTISEMENT
Markets/EquitiesArticle

Nomad Foods shares rise 4.6% after insider buys, Q2 beat

Nomad Foods shares climbed 4.6% to $12.35 after CFO Ruben Baldew purchased 28,290 shares and Q2 results topped estimates. Analysts remain cautious despite the gains.

PA
Priya Anand · Equities & Earnings Desk · 24 Aug 2026 · 17:14 · 1 min read
Share
Nomad Foods shares rise 4.6% after insider buys, Q2 beat

Nomad Foods shares rose 4.6% to $12.35 during mid-day trading on Thursday, extending gains after the company reported second-quarter results that exceeded expectations.

The food producer’s adjusted earnings per share came in at $0.39, surpassing consensus estimates, while revenue totaled $724 million, also beating projections. The company reduced its full-year earnings guidance, citing higher refinancing costs as a headwind.

Insider activity added to the momentum after Chief Financial Officer Ruben Baldew purchased 28,290 ordinary shares on the open market on August 19 at approximately $11.85 per share. The transaction increased his direct stake to 367,172 shares. The regulatory filing was submitted on August 21. Other executives, including CEO Dominic Brisby, co-founders, and director Ian Ashken, have also made substantial open-market purchases in recent months.

The stock remains well below its 52-week high of $15.91, reflecting broader market caution despite the company’s defensive consumer staple profile and attractive dividend yield. The S&P 500 and Nasdaq were modestly lower, while the Dow Jones edged higher, underscoring mixed market sentiment.

Analysts at Zacks Research maintained a cautious stance, downgrading Nomad Foods to a Strong Sell rating.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
Share this story
PA
Written by
Priya Anand
Equities & Earnings Desk

Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.

More from Priya Anand →
ADVERTISEMENT
ADVERTISEMENT